

Article

Design, Synthesis and Anti-Platelet Aggregation Activity Study of Ginkgolide-1,2,3-triazole Derivatives

Jian Cui ^{1,†}, Le'An Hu ^{1,2,†}, Wei Shi ³, Guozhen Cui ^{3,*}, Xumu Zhang ^{2,*} and Qing-Wen Zhang ^{1,*}

¹ State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China; mb65822@umac.mo (J.C.); yb67526@umac.mo (L.H.)

² Department of Chemistry and Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen 518000, China

³ Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, Guangdong, China; diana1354726@outlook.com

* Correspondence: cgzum@hotmail.com (G.C.); zhangxm@sustc.edu.cn (X.Z.); qwzhang@umac.mo (Q.-W.Z.)

† These authors contributed equally to the work.

Received: 7 May 2019; Accepted: 3 June 2019; Published: 7 June 2019



Abstract: Ginkgolides are the major active component of *Ginkgo biloba* for inhibition of platelet activating factor receptor. An azide-alkyne Huisgen cycloaddition reaction was used to introduce a triazole nucleus into the target ginkgolide molecules. A series of ginkgolide-1,2,3-triazole conjugates with varied functional groups including benzyl, phenyl and heterocycle moieties was thus synthesized. Many of the designed derivatives showed potent antiplatelet aggregation activities with IC₅₀ values of 5~21 nM.

Keywords: ginkgolide; platelet-activating factor receptor; inhibitor

1. Introduction

Ginkgo biloba, also named maidenhair tree, the only surviving species from the family Ginkgoaceae has existed for more than 180 million years, and for this reason it was called a “living fossil” by Darwin. *G. biloba* has been used as a traditional Chinese medicine for a long time for the treatment of lung weakness, asthma, coughing, cancer, etc [1,2]. Ginkgo has also been popular in the Western world since 1965, when a German company developed from ginkgo extracts a botanical medicine named EGB761, with various effects on central nervous system (CNS) diseases, including Alzheimer’s disease, dementia, hypomnesia, etc [3,4]. The main components of ginkgo extracts are terpene trilactones (including ginkgolides and bilobalide) and flavonoids [5,6]. Since flavonoids are deemed to hardly penetrate the blood-brain barrier, it is assumed the terpene trilactones from ginkgo extracts should be the major active components for the CNS effects and cardiovascular activity [7,8]. As a natural phospholipid agonist of the platelet activating factor of platelet activating factor receptor (PAFR), platelet activating factor (PAF) regulates various physiological activities of the CNS and peripheral nervous system, including platelet aggregation, blood pressure regulation, inflammation, long-term enhancement of CNS, etc [9]. It’s reported that ginkgolides could competitively inhibit the platelet-activating factor receptor (PAFR), resulting in the observed CNS protection and antithrombotic effects [10,11].

To date, 10 ginkgolides (ginkgolide A~Q) [5,6,12] and two bilobalides (bilobalide and bilobanol) [13,14] have been isolated and from *G. biloba* and their structures elucidated. Most natural ginkgolides displayed significant activity against PAFR, while the bilobalides didn’t. In particular, ginkgolide B is the most potent PAFR antagonist discovered in nature [1]. Since the 1970s, many investigations on the structural modifications and structure-activity relationship of ginkgolides

have been conducted. It is revealed that both ring C and ring D are essential for anti-PAFR activity [15]. Substituents at the C-7 position decrease the activity [16]. It's noteworthy that the introduction of bulky or aromatic substituents at 10-OH could help to increase activity against PAFR [17,18]. The 1,2,3-triazole moiety, also known simply as triazole, acts as an important structural fragment widely used to construct new drug molecules [19]. The triazole is an electron isostere of the amide group, which easily forms hydrogen bonds, coordination bonds, etc., helping to form a variety of non-covalent bond interactions with target proteins [19,20].


In this paper, a series of ginkgolide derivatives with 1,2,3-triazole moieties connected with various benzyl, phenyl and heterocycle moieties at the C-10 position were designed and synthesized. Their antiplatelet aggregation activities were also evaluated and several derivatives displayed more potent inhibitory effects against PAFR than the natural ginkgolide B, with IC₅₀ values of 5~21 nM, or about 10 to 20 times higher than the natural compound.

2. Results and Discussion

2.1. Chemistry

Drugability is improved when the triazole moiety is introduced into some leads [20]. The azide-alkyne Huisgen cycloaddition reaction, also known as the Huisgen 1,3-dipolar cycloaddition, has been proved to be a powerful tool in construction of triazoles [21]. In this reaction, the azide moiety reacts to a terminal alkyne group to form the triazole ring. The copper(I) catalyst improves both the reaction rate and selectivity. A series of ginkgolide-1,2,3-triazole conjugates with varied functional groups including benzyl, phenyl and heterocycle moieties was synthesized via this method.


10-O-Propargylated ginkgolide B (**3**) was synthesized in 65% yield by mixing ginkgolide B (**1**) and 3-bromoprop-1-yne (**2**) with potassium carbonate in anhydrous acetonitrile for several hours (Scheme 1). 10-O-Propargylated ginkgolide A (**3'**) and 10-O-propargylated ginkgolide C (**3''**) were obtained in 32% and 69% yield, respectively from the corresponding ginkgolide A (**1'**) and ginkgolide C (**1''**) following the same scheme.




Scheme 1. Formation of 10-O-propargylated ginkgolides **3**, **3'** and **3''**.

The target molecules, 10-substituted 1,2,3-triazole-ginkgolide B derivatives **5**, were synthesized using the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction [21] by mixing 10-O-propargylated ginkgolide B (**3**) with a series of azides **4** in a three-phase solvent, using copper(I) as catalyst (Scheme 2). The 1,2,3-triazole-ginkgolide A derivatives (**5'**) and 1,2,3-triazole-ginkgolide ginkgolide C derivatives (**5''**) were obtained by the same route.

Azides **4a–4ee** were synthesized by firstly mixing the corresponding aniline, sodium nitrite and concentrated hydrochloride in ethyl acetate at 0 °C for 30 min, then adding sodium azide to the system at room temperature and stirring for another two hours (Scheme 3) [22–24]. The resulting products are listed in Table 1.



Scheme 2. Formation of 10-substituted 1,2,3-triazole-ginkgolide derivatives 5, 5' and 5''.




Scheme 3. Preparation of azides 4a–4ee.

Table 1. Synthesized azides 4a–4ee.


Entry	Azide	Ar	Yield
1	4a	Ph	77
2	4b	2-Cl-Ph	88
3	4c	3-Cl-Ph	91
4	4d	4-Cl-Ph	75
5	4e	2-Cl, 6Cl-Ph	72
6	4f	2-Cl, 4Cl-Ph	71
7	4g	3-Cl, 4Cl-Ph	87
8	4h	3-F-Ph	88
9	4i	3-CF ₃ , 4-Cl-Ph	62
10	4j	4-OCF ₃ -Ph	86
11	4k	3-CF ₃ , 5-CF ₃ Ph	91
12	4l	4-tertbutyl-Ph	76
13	4m	3-Br-Ph	62
14	4n	2-Me-Ph	75
15	4o	2-OH-Ph	92
16	4p	2-CN-Ph	88
17	4q	3-Me-Ph	74
18	4r	3-isopropyl-Ph	87
19	4s	3-COOEt-Ph	78
20	4t	3-COOH-Ph	78
21	4u	4-Me-Ph	65
22	4v	4-OMe-Ph	87
23	4w	4-F-Ph	74
24	4x	4-Br-Ph	63
25	4y	4-CF ₃ -Ph	77
26	4z	4-NO ₂ -Ph	67
27	4aa	4-COOMe-Ph	87
28	4bb	4-COOH-Ph	76
29	4cc	3-OMe,5-OMe-Ph	79
30	4dd	3-Cl, 4F-Ph	87
31	4ee	3-pyridine	68

Azides 4ff–4gg were synthesized by mixing the corresponding benzyl bromide and sodium azide in DMF for two hours (Scheme 4) [22,25]. The resulting products are listed in Table 2.

Scheme 4. Preparation of azides **4ff**, **4gg**.Table 2. Synthesized azides **4ff–4gg**.

Entry	Azide	Ar	Yield
1	4ff	Bn	82
2	4gg	2-Me-Bn	77

Following the reaction shown in Scheme 2, using 10-O-propargylated ginkgolide B **3** and azides **4a–4gg**, compounds **5a–5gg** were obtained (Figure 1).

Figure 1. Structures of 10-substituted 1,2,3-triazole-ginkgolide B derivatives **5a–5gg**.

Following the reaction shown in Scheme 2, using 10-*O*-propargylated ginkgolide A **3'**, 10-*O*-propargylated ginkgolide C **3''** and azides **4a**, **4n**, **4p**, **4ff**, **4gg**, compounds **5'a-5'gg**, **5''a-5''gg** were obtained as illustrated in Figure 2.




Figure 2. Structures of 10-substituted 1,2,3-triazole-ginkgolide A derivatives **5'a-5'gg** and 10-substituted 1,2,3-triazole-ginkgolide C derivatives **5''a-5''gg**.

2.2. Biology

Since ginkgolide derivatives have shown antiplatelet aggregation activities as reported before [15–18], the as-synthesized ginkgolide-1,2,3-triazole derivatives were expected to show improved biological potency.

Firstly, the newly synthesized 10-substituted 1,2,3-triazole-ginkgolide B derivatives (**5**) were tested by the method of Born [26,27]. The result was given in Figure 3. Which showed some of them exhibited considerable activity better than ginkgolide B. The best results were obtained with compounds **5a**, **5n**, **5p**, **5ff** and **5gg**.

From the results shown above, we can preliminarily conclude that non-substituted benzyl (compound **5a**) and phenyl (compound **5ff**) 1,2,3-triazole conjugates have significantly enhanced antiplatelet aggregation activities compared to ginkgolide B (**1**). We can also see that the substitution at the *meta*- or/and *para*- positions of the benzyl group reduce the activity. Some small steric hindrance groups (such as methyl and cyano groups) substituted at the *ortho*-position of the phenyl (compounds **5n** and **5p**) and benzyl (compound **5gg**) groups maintain or slightly reduce the activity.




Figure 3. Antiplatelet aggregation activities of the 10-substituted 1,2,3-triazole-ginkgolide B derivatives. Ginkgolide B (**1**) was used as reference.

In further studies, 10-substituted 1,2,3-triazole-ginkgolide A **5'** and ginkgolide C **5''** derivatives, having the same moieties as the most active ginkgolide B derivatives **5a**, **5n**, **5p**, **5ff** and **5gg**, were synthesized and their antiplatelet aggregation activities tested and reported as inhibition ratios at 50 nM). The results are shown in Figure 4. Some of them exhibit better activity than not only their precursors **1'** or **1''**, but also ginkgolide B (**1**). The best results were obtained with compounds **5'a**, **5'ff**, **5'gg** and **5''gg**.




Figure 4. Antiplatelet aggregation activity activities of the 10-substituted 1,2,3-triazole-ginkgolide A and ginkgolide C derivatives. Ginkgolide B (**1**), ginkgolide A (**1'**) and ginkgolide C (**1''**) were used as reference.


The most active compounds obtained by method above, **5a**, **5n**, **5p**, **5q**, **5ff**, **5gg**, **5'a**, **5'ff**, **5'gg** and **5''gg**, were further examined in order to get their activity expressed as an IC_{50} value. The results are listed in Table 3.

As we can see, compounds **5a**, **5p**, **5ff**, **5gg** and **5'a** display promising antiplatelet aggregation activity with IC_{50} values ranging from 5–21 nM. Among them compounds **5ff** and **5gg** were the best among the series of compounds, showing about a 20-fold increase in comparison with the natural ginkgolide B (**1**).

Table 3. In vitro antiplatelet aggregation activity study of some of ginkgolide-1,2,3-triazole derivatives.

Compound	PAF-Induced Platelet Aggregation IC ₅₀ (nM)	Compound	PAF-Induced Platelet Aggregation IC ₅₀ (nM)
1	130.1 ± 20.0	5ff	5.31 ± 1.84
1'	580.4 ± 50.3	5gg	5.68 ± 0.71
1''	7540 ± 662	5'a	18.55 ± 2.25
5a	7.74 ± 1.89	5'ff	25.37 ± 4.25
5n	20.63 ± 2.84	5'gg	71.47 ± 6.26
5p	10.19 ± 2.03	5''gg	37.68 ± 4.17
5q	44.33 ± 4.42		

In order to verify if the most active ginkgolide-1,2,3-triazole derivatives could also be considered as potential antiplatelet aggregation therapeutics, compounds **5a**, **5n**, **5p**, **5q**, **5ff**, **5gg**, **5'a**, **5'ff** and **5''gg** were examined to confirm their cytotoxicity using an LDH assay [28]. The results are shown in Figure 5.

**Figure 5.** Cytotoxicity of some of ginkgolide-1,2,3-triazole derivatives: (a) Tested at 1 μM concentration. (b) Tested at 10 μM concentration. Ginkgolide B (1) was used as reference.

In addition, compounds **5a**, **5p**, **5ff**, **5gg** and **5'a** were examined to confirm their toxicity on platelets using the LDH assay [29]. The results are shown in Figure 6.




Figure 6. Toxicity on platelets of some of ginkgolide-1,2,3-triazole derivatives: (a) Tested at 1 μM concentration. (b) Tested at 10 μM concentration. Ginkgolide B (**1**) was used as reference.

As shown in results above, these most active compounds did not demonstrate toxicity towards cardiomyocytes and platelets ($p > 0.05$) up to 10 μM (almost two order of magnitude higher than IC_{50} of ginkgolide B), which suggest that they have a broad therapeutic window/safety window.

3. Materials and Methods

3.1. Compound Synthesis

3.1.1. General Experimental Procedures

All solvents and reagents of analytical grade were obtained from commercial sources. Flash chromatography was performed using silica gel (200–300 mesh, Qingdao Marine Chemical Group Co., Qingdao, China). All reactions were monitored by TLC on silica gel plates (Merck, Darmstadt, Germany). NMR spectra were recorded in CDCl_3 or DMSO at 400 or 600 MHz for ^1H -NMR and 125 or 150 MHz for ^{13}C -NMR on an Ascent 400 or 600 spectrometer (Bruker, Fallanden, Switzerland). The solvent signal was used as an internal standard. ESI-MS were recorded on a 1200/MSD mass spectrometer (Agilent, Santa Clara, CA, USA). HREIMS were recorded on a LTQ Orbitrap XL mass spectrometer (Thermo, Bremen, Germany).

3.1.2. General Procedures for the Preparation 10-O-propargylated Ginkgolides

Propargyl bromide (2.4 mmol) were slowly added to a mixture of ginkgolide (**1**, **1'** or **1''**, 2.0 mmol) and K_2CO_3 (4.0 mmol) in acetonitrile (15 mL). The reaction mixture was refluxed for 24 h under an argon atmosphere and then was extracted with EtOAc three times. The combined organic phases

were dried over anhydrous MgSO_4 , filtered, and concentrated in vacuo. The residue was purified by chromatography (SiO_2 , petroleum ether (PE)/EtOAc stepwise elution, 1:1 to EtOAc).

10-O-Propargylated ginkgolide B (3). Following the described procedure, 602 mg (65%) of compound **3** were obtained from 829 mg (2.0 mmol) of ginkgolide B (**1**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 6.46 (s, 1H), 6.14 (s, 1H), 5.32 (d, $J = 4.1$ Hz, 1H), 5.19 (s, 1H), 5.15 (d, $J = 4.9$ Hz, 1H), 4.69 (ddd, $J = 70.7, 15.8, 2.5$ Hz, 2H), 4.61 (d, $J = 6.8$ Hz, 1H), 4.09 (dd, $J = 6.9, 4.9$ Hz, 1H), 3.62 (t, $J = 2.4$ Hz, 1H), 2.84 (q, $J = 7.1$ Hz, 1H), 2.13 (dd, $J = 13.6, 4.6$ Hz, 1H), 1.99 (s, 1H), 1.87 (td, $J = 13.9, 4.2$ Hz, 1H), 1.71 (dd, $J = 14.4, 4.5$ Hz, 1H), 1.11 (d, $J = 7.2$ Hz, 3H), 1.05 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.77, 172.56, 170.63, 110.02, 99.51, 93.37, 83.06, 79.71, 79.29, 74.96, 74.12, 72.41, 67.84, 60.23, 57.91, 49.08, 41.96, 36.96, 32.29, 29.38 (3C), 8.44. HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{26}\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 463.1599, found 463.1531.

10-O-Propargylated ginkgolide A (3'). Following the described procedure, 286 mg (32%) of compound **3'** were obtained from 797 mg (2.0 mmol) of ginkgolide A (**1'**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 6.43 (s, 1H), 6.12 (s, 1H), 5.10 (s, 1H), 5.00 (d, $J = 4.1$ Hz, 1H), 4.86 (t, $J = 7.7$ Hz, 1H), 4.72 (dd, $J = 15.6, 2.5$ Hz, 1H), 4.50 (dd, $J = 15.5, 2.5$ Hz, 1H), 3.59 (s, 1H), 3.17 (d, $J = 5.2$ Hz, 1H), 2.91 (q, $J = 7.2$ Hz, 1H), 2.75 (dd, $J = 15.1, 7.2$ Hz, 1H), 2.08 (dd, $J = 13.7, 4.8$ Hz, 1H), 1.99 (s, 1H), 1.95 (dd, $J = 13.8, 4.3$ Hz, 1H), 1.82 (dd, $J = 15.1, 8.2$ Hz, 1H), 1.72 (dd, $J = 14.1, 4.8$ Hz, 1H), 1.23 (s, 2H), 1.12 (d, $J = 7.2$ Hz, 3H), 1.03 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.91, 172.75, 170.96, 110.08, 100.94, 87.95, 86.48, 85.31, 79.49, 78.95, 75.32, 68.67, 66.83, 57.81, 49.07, 49.03, 36.78, 36.45, 32.25, 29.24 (3C), 8.64. HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{26}\text{O}_9$ $[\text{M} + \text{H}]^+$: 447.1650, found 447.1582.

10-O-Propargylated ginkgolide C (3''). Following the described procedure, 669 mg (69%) of compound **3''** were obtained from 861 mg (2.0 mmol) of ginkgolide A (**1''**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 6.47 (s, 1H), 6.17 (s, 1H), 5.68 (d, $J = 6.1$ Hz, 1H), 5.26 (d, $J = 5.0$ Hz, 1H), 5.18 (s, 1H), 4.71 (ddd, $J = 67.5, 15.8, 2.5$ Hz, 2H), 4.59 (d, $J = 6.6$ Hz, 1H), 4.06–4.01 (m, 2H), 3.99 (ddd, $J = 12.6$ Hz, 6.1 Hz, 4.3 Hz, 1H), 3.63 (s, 1H), 2.82 (q, $J = 7.1$ Hz, 1H), 2.50 (s, 2H), 1.99 (s, 2H), 1.54 (d, $J = 12.5$ Hz, 1H), 1.18 (t, $J = 7.1$ Hz, 2H), 1.12 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.73, 172.50, 170.90, 109.86, 99.26, 93.45, 83.06, 79.82, 79.29, 74.79, 74.17, 73.95, 67.05, 64.01, 60.23, 58.01, 49.26, 41.94, 32.20, 21.23 (3C), 8.48. HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{26}\text{O}_{11}$ $[\text{M} + \text{H}]^+$: 479.1548, found 479.1472.

3.1.3. General Procedures for the Preparation of 10-Substituted 1,2,3-triazole-Ginkgolide Derivatives

Sodium ascorbate (0.03 mmol) and CuSO_4 (0.01 mmol) were added in single portions to a solution of 10-O-propargylated ginkgolide **3**, **3'** or **3''** (0.1 mmol) and corresponding azide **4** (0.11 mmol) in 1:1:1 t-BuOH/ H_2O /THF (3 mL). The reaction mixture was stirred at room temperature for 48 h under an argon atmosphere and then was extracted with EtOAc three times. The combined organic phases were dried over anhydrous MgSO_4 , filtered, and concentrated in vacuo. The residue was purified by chromatography (SiO_2 , PE/EtOAc 1:3 stepwise elution to EtOAc) to afford the appropriate compound **5**.

10-O-(1-Phenyl-1H-1,2,3-triazole) ginkgolide B (5a). Following the described procedure, 42.3 mg (73%) of compound **5a** were obtained from 46.2 mg (0.1 mmol) of 10-O-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 8.798 (1H, s), 7.88 (d, $J = 7.6$ Hz, 2H), 7.50–7.64 (m, 3H), 6.47 (s, 1H), 6.20 (s, 1H), 5.52 (d, $J = 4.4$ Hz, 1H), 5.45 (d, $J = 12.0$ Hz, 1H), 4.93 (d, $J = 12.0$ Hz, 1H), 4.63 (d, $J = 6.8$ Hz, 1H), 4.21 (dd, $J = 6.8$ Hz, 4.8 Hz, 1H), 2.88 (q, $J = 6.8$ Hz, 1H), 2.11 (dd, $J = 13.6$ Hz, 4.0 Hz, 1H), 1.84 (ddd, $J = 14.0$ Hz, 13.6 Hz, 4.0 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.13 (d, $J = 7.2$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (125 MHz, $\text{DMSO-}d_6$) δ 176.32, 172.51, 170.12, 143.76, 136.46, 129.96 (2C), 128.94, 121.59, 120.23 (2C), 109.68, 98.88, 92.62, 82.47, 78.49, 75.16, 73.77, 71.96, 67.34, 63.00, 48.73, 41.56, 36.54, 31.73, 28.64 (3C), 7.84. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{31}\text{N}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 582.2082, found 582.2062.

10-O-(1-(2-Chlorophenyl)-1H-1,2,3-triazole) ginkgolide B (5b). Following the described procedure, 21.0 mg (34%) of compound **5b** were obtained from 46.2 mg (0.1 mmol) of 10-O-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 7.78 (d, $J = 1.2$ Hz, 1H), 7.58–7.71 (m, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.50 (d, $J = 4.8$ Hz, 1H), 5.46 (d, $J = 12.0$ Hz, 1H), 5.33–5.35 (m, 2H), 4.97 (d, $J = 12.0$ Hz, 1H), 4.64 (d, $J = 7.2$ Hz, 1H), 4.21 (dd, $J = 7.2$ Hz, 4.8 Hz, 1H), 2.88 (q, $J = 7.0$ Hz, 1H), 2.12 (dd, $J = 13.6$ Hz, 4.0 Hz, 1H), 1.85 (ddd, $J = 14.4$ Hz, 13.4 Hz, 4.0 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.12 (d,

$J = 6.8$ Hz, 3H), 1.02 (s, 9H), 176.30, 172.47, 170.10, 142.91, 134.30, 131.77, 130.60, 128.52, 128.39, 128.31, 125.43, 109.67, 98.86, 92.58, 82.46, 78.47, 75.25, 73.74, 71.93, 67.32, 63.07, 48.72, 41.55, 36.51, 31.72, 28.65 (3C), 8.57 (s, 1H). $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ 7.82, 7.80 (d, $J = 1.2$ Hz, 1H). HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{30}\text{ClN}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 616.1692, found 616.1670.

10-O-(1-(3-Chlorophenyl)-1H-1,2,3-triazole) ginkgolide B (5c). Following the described procedure, 40.1 mg (65%) of compound **5c** were obtained as method 1, from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 8.87 (s, 1H), 8.02 (s, 1H), 7.59–7.91 (m, 3H), 6.47 (s, 1H), 6.20 (s, 1H), 5.43–5.46 (m, 2H), 5.33 (s, 2H), 4.93 (d, $J = 12.0$ Hz, 1H), 4.64 (d, $J = 6.8$ Hz, 1H), 4.20 (dd, $J = 7.0$ Hz, 4.6 Hz, 1H), 2.88 (q, $J = 6.8$ Hz, 1H), 2.11 (dd, $J = 13.0$ Hz, 3.8 Hz, 1H), 1.86 (ddd, $J = 14.2$ Hz, 13.4 Hz, 3.8 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.12 (d, $J = 6.8$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ 176.28, 172.46, 170.08, 143.82, 137.48, 134.20, 131.69, 128.74, 121.91, 120.02, 118.84, 109.66, 98.88, 92.60, 82.47, 78.45, 75.14, 73.75, 71.93, 67.29, 62.90, 48.71, 41.53, 36.51, 31.70, 28.62 (3C), 7.82. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{30}\text{ClN}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 616.1692, found 616.1674.

10-O-(1-(4-Chlorophenyl)-1H-1,2,3-triazole) ginkgolide B (5d). Following the described procedure, 20.3 mg (33%) of compound **5d** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 8.82 (s, 1H), 7.68–7.94 (dd, 4H), 6.47 (s, 1H), 6.20 (s, 1H), 5.43–5.48 (m, 2H), 5.32–5.33 (m, 2H), 4.92 (d, $J = 8.0$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.20 (dd, $J = 7.0$ Hz, 4.6 Hz, 1H), 2.88 (q, $J = 6.8$ Hz, 1H), 2.11 (dd, $J = 13.0$ Hz, 3.8 Hz, 1H), 1.83 (ddd, $J = 14.4$ Hz, 13.2 Hz, 4.0 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.13 (d, $J = 7.2$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ 176.28, 172.46, 170.08, 143.87, 135.24, 133.19, 129.91 (2C), 121.90 (2C), 121.73, 109.66, 98.87, 92.60, 82.46, 78.45, 75.16, 73.74, 71.92, 67.30, 62.93, 48.70, 41.53, 36.51, 31.70, 28.62 (3C), 7.81. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{30}\text{ClN}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 616.1692, found 616.1671.

10-O-(1-(2,6-Dichlorophenyl)-1H-1,2,3-triazole) ginkgolide B (5e). Following the described procedure, 34.5 mg (53%) of compound **5e** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 8.54 (s, 1H), 7.68–7.81 (m, 3H), 6.48 (s, 1H), 6.20 (s, 1H), 5.47 (d, $J = 12.0$ Hz, 1H), 5.32–5.54 (m, 2H), 5.24 (d, $J = 4.4$ Hz, 1H), 4.99 (d, $J = 12.4$ Hz, 1H), 4.64 (d, $J = 7.2$ Hz, 1H), 4.19 (dd, $J = 7.2$ Hz, 4.6 Hz, 1H), 2.87 (q, $J = 7.2$ Hz, 1H), 2.13 (dd, $J = 13.2$ Hz, 4.0 Hz, 1H), 1.84 (ddd, $J = 14.2$ Hz, 13.4 Hz, 4.0 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.12 (d, $J = 7.2$ Hz, 3H), 1.03 (s, 9H). $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ 176.27, 172.38, 170.07, 143.11, 133.04, 132.58 (2C), 132.42, 129.26 (2C), 125.88, 109.68, 98.82, 92.40, 82.48, 78.45, 75.51, 73.74, 71.91, 67.28, 63.20, 48.68, 41.54, 36.50, 31.74, 28.69 (3C), 7.80. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{29}\text{Cl}_2\text{N}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 650.1303, found 650.1287.

10-O-(1-(2,4-Dichlorophenyl)-1H-1,2,3-triazole) ginkgolide B (5f). Following the described procedure, 29.3 mg (45%) of compound **5f** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 8.57 (s, 1H), 8.02 (d, $J = 2.4$ Hz, 1H), 7.68–7.76 (m, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.43–5.48 (m, 2H), 5.33–5.40 (m, 2H), 4.96 (d, $J = 12.4$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.20 (dd, $J = 7.2$ Hz, 4.8 Hz, 1H), 2.88 (q, $J = 6.8$ Hz, 1H), 2.12 (dd, $J = 12.8$ Hz, 4.0 Hz, 1H), 1.84 (ddd, $J = 14.2$ Hz, 13.2 Hz, 4.0 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.12 (d, $J = 6.8$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ 176.27, 172.44, 170.07, 143.02, 135.51, 133.34, 130.16, 129.64, 129.49, 128.65, 125.51, 109.65, 98.85, 92.58, 82.45, 78.44, 75.27, 73.71, 71.91, 67.30, 63.03, 59.71, 48.69, 41.53, 36.49, 31.71, 28.64 (3C), 7.81. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{29}\text{Cl}_2\text{N}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 650.1303, found 650.1289.

10-O-(1-(3,5-Dichlorophenyl)-1H-1,2,3-triazole) ginkgolide B (5g). Following the described procedure, 38.3 mg (34%) of compound **5g** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 8.92 (s, 1H), 8.05 (d, $J = 1.6$ Hz, 2H), 7.80 (t, $J = 1.6$ Hz, 1H), 6.48 (s, 1H), 6.20 (s, 1H), 5.44 (d, $J = 12.0$ Hz, 1H), 5.36 (d, $J = 4.8$ Hz, 1H), 5.32–5.35 (m, 2H), 4.93 (d, $J = 12.0$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.20 (dd, $J = 7.2$ Hz, 4.6 Hz, 1H), 2.87 (q, $J = 7.2$ Hz, 1H), 2.11 (dd, $J = 12.8$ Hz, 4.0 Hz, 1H), 1.83 (ddd, $J = 14.4$ Hz, 13.2 Hz, 4.0 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.0 Hz, 1H), 1.12 (d, $J = 7.2$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ 176.28, 172.43, 170.08, 143.90, 138.05, 135.26 (2C), 128.27, 122.22, 118.98, 118.88, 109.66, 98.91, 92.60, 82.49, 78.44,

75.17, 73.75, 71.93, 67.28, 62.84, 48.71, 41.52, 36.51, 31.71, 28.62 (3C), 7.84. HRMS (ESI): m/z calcd for $C_{29}H_{29}Cl_2N_3O_{10}$ [M + H]⁺: 650.1303, found 650.1287.

10-O-(1-(3-Fluorophenyl)-1H-1,2,3-triazole) ginkgolide B (5h). Following the described procedure, 32.4 mg (54%) of compound **5h** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 7.99 (s, 1H), 7.16–7.54 (m, 4H), 6.01 (s, 1H), 5.67 (d, *J* = 11.6 Hz, 1H), 5.53 (d, *J* = 3.6 Hz, 1H), 5.05 (d, *J* = 4.4 Hz, 1H), 4.96 (s, 1H), 4.91 (d, *J* = 11.2 Hz, 1H), 4.64 (d, *J* = 7.6 Hz, 1H), 4.40 (dd, *J* = 7.6 Hz, 4.4 Hz, 1H), 3.07 (q, *J* = 6.8 Hz, 1H), 2.84 (s, 1H), 2.28 (dd, *J* = 12.8 Hz, 4.2 Hz, 1H), 2.05 (ddd, *J* = 16.8 Hz, 10.8 Hz, 4.0 Hz, 1H), 1.98 (dd, *J* = 14.2 Hz, 4.2 Hz, 1H), 1.30 (d, *J* = 6.8 Hz, 3H), 1.13 (s, 9H). ¹³C-NMR (125 MHz, DMSO-*d*₆) δ 176.28, 172.46, 170.08, 143.86, 137.64, 131.93, 121.85, 116.14, 115.66, 109.66, 107.83, 107.62, 92.60, 82.47, 78.45, 75.17, 73.75, 71.93, 67.30, 62.92, 48.71, 41.53, 36.51, 31.71, 28.62 (3C), 7.82. HRMS (ESI): m/z calcd for $C_{29}H_{31}FN_3O_{10}$ [M + H]⁺: 600.1993, found 600.2014.

10-O-(1-(4-Chloro-3-trifluoromethylphenyl)-1H-1,2,3-triazole) ginkgolide B (5i). Following the described procedure, 27.9 mg (41%) of compound **5i** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 8.07 (s, 1H), 7.70–8.09 (m, 3H), 6.01 (s, 1H), 5.65 (d, *J* = 11.6 Hz, 1H), 5.52 (d, *J* = 4.0 Hz, 1H), 5.06 (d, *J* = 4.0 Hz, 1H), 4.97 (s, 1H), 4.91 (d, *J* = 11.6 Hz, 1H), 4.62 (d, *J* = 8.0 Hz, 1H), 4.38 (dd, *J* = 7.6 Hz, 4.4 Hz, 1H), 3.07 (q, *J* = 7.0 Hz, 1H), 2.98 (s, 1H), 2.28 (dd, *J* = 12.8 Hz, 4.0 Hz, 1H), 2.04 (ddd, *J* = 14.0 Hz, 13.2 Hz, 4.0 Hz, 1H), 1.95 (dd, *J* = 14.4 Hz, 4.0 Hz, 1H), 1.30 (d, *J* = 6.8 Hz, 3H), 1.12 (s, 9H). ¹³C-NMR (125 MHz, DMSO-*d*₆) δ 176.27, 172.44, 170.07, 143.99, 135.40, 133.39, 130.69, 128.15, 127.83, 125.51, 122.25, 119.60, 109.66, 98.88, 92.56, 82.47, 78.43, 75.19, 73.74, 71.93, 67.28, 62.84, 48.70, 41.53, 36.50, 31.70, 28.62 (3C), 7.82. HRMS (ESI): m/z calcd for $C_{30}H_{29}ClF_3N_3O_{10}$ [M + H]⁺: 684.1566, found 684.1544.

10-O-(1-(4-Trifluoromethoxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5j). Following the described procedure, 20.6 mg (31%) of compound **5j** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 8.83 (s, 1H), 8.03 (d, *J* = 9.0 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.43–5.49 (m, 2H), 5.32–5.34 (m, 2H), 4.93 (d, *J* = 12.0 Hz, 1H), 4.62 (d, *J* = 7.2 Hz, 1H), 4.21 (dd, *J* = 7.2 Hz, 4.6 Hz, 1H), 2.88 (q, *J* = 7.0 Hz, 1H), 2.11 (dd, *J* = 13.2 Hz, 4.0 Hz, 1H), 1.84 (ddd, *J* = 14.2 Hz, 13.4 Hz, 4.0 Hz, 1H), 1.73 (dd, *J* = 14.4 Hz, 4.0 Hz, 1H), 1.13 (d, *J* = 7.2 Hz, 3H), 1.02 (s, 9H). ¹³C-NMR (125 MHz, DMSO-*d*₆) δ 176.28, 172.46, 170.08, 148.02, 143.91, 135.30, 122.63 (2C), 122.30 (2C), 121.97, 121.00, 109.66, 98.87, 92.61, 82.46, 78.45, 75.17, 73.74, 71.93, 67.30, 62.94, 48.71, 41.53, 36.51, 31.70, 28.62 (3C), 7.81. HRMS (ESI): m/z calcd for $C_{30}H_{30}F_3N_3O_{11}$ [M + H]⁺: 666.1905, found 666.1887.

10-O-(1-(3,5-Difluoromethylphenyl)-1H-1,2,3-triazole) ginkgolide B (5k). Following the described procedure, 32.3 mg (45%) of compound **5k** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 9.14 (s, 1H), 8.62 (s, 2H), 8.31 (s, 1H), 6.48 (s, 1H), 6.21 (s, 1H), 5.47 (d, *J* = 12.0 Hz, 1H), 5.35 (s, 1H), 5.30–5.33 (m, 2H), 4.96 (d, *J* = 12.0 Hz, 1H), 4.64 (d, *J* = 7.2 Hz, 1H), 4.21 (dd, *J* = 7.2 Hz, 4.8 Hz, 1H), 2.88 (q, *J* = 6.8 Hz, 1H), 2.12 (dd, *J* = 12.8 Hz, 4.0 Hz, 1H), 1.71–1.87 (m, 2H), 1.13 (d, *J* = 6.8 Hz, 3H), 1.03 (s, 9H). ¹³C-NMR (125 MHz, DMSO-*d*₆) δ 176.28, 172.44, 170.07, 144.01, 137.73, 132.00 (2C), 131.73 (2C), 123.81, 122.64, 121.64, 121.07, 109.68, 98.90, 92.54, 82.49, 78.42, 75.22, 73.77, 71.94, 62.78, 48.71, 41.53, 36.50, 31.71, 28.63 (3C), 7.83. HRMS (ESI): m/z calcd for $C_{31}H_{29}F_6N_3O_{10}$ [M + H]⁺: 718.1830, found 718.1808.

10-O-(1-(4-tert-Butylphenyl)-1H-1,2,3-triazole) ginkgolide B (5l). Following the described procedure, 35.0 mg (55%) of compound **5l** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 8.75 (s, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.62 (d, *J* = 8.8 Hz, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.58 (d, *J* = 4.4 Hz, 1H), 5.44 (d, *J* = 12.0 Hz, 1H), 5.33 (s, 2H), 4.93 (d, *J* = 12.0 Hz, 1H), 4.63 (d, *J* = 7.2 Hz, 1H), 4.21 (dd, *J* = 7.2 Hz, 4.6 Hz, 1H), 2.88 (q, *J* = 7.2 Hz, 1H), 2.11 (dd, *J* = 13.2 Hz, 4.0 Hz, 1H), 1.83 (ddd, *J* = 14.4 Hz, 13.2 Hz, 4.0 Hz, 1H), 1.73 (dd, *J* = 14.4 Hz, 3.8 Hz, 1H), 1.33 (s, 9H), 1.13 (d, *J* = 7.2 Hz, 3H), 1.01 (s, 9H). ¹³C-NMR (125 MHz, DMSO-*d*₆) δ 176.29, 172.50, 170.08, 150.60, 143.60, 134.13, 126.64 (2C), 121.49, 119.98 (2C), 109.65, 98.84, 92.60, 82.43, 78.46, 75.09, 73.73,

71.93, 67.32, 62.97, 48.71, 41.54, 36.51, 34.50, 31.70, 30.95 (3C), 28.62 (3C), 7.80. HRMS (ESI): m/z calcd for $C_{33}H_{39}N_3O_{10}$ $[M + H]^+$: 638.2708, found 638.2689.

10-O-(1-(3-Bromophenyl)-1H-1,2,3-triazole) ginkgolide B (5m). Following the described procedure, 38.3 mg (58%) of compound **5m** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (400 MHz, DMSO- d_6) δ 8.87 (s, 1H), 8.14 (t, $J = 2.0$ Hz, 1H), 7.94 (dd, $J = 8.2$ Hz, 1.4 Hz, 1H), 7.73 (d, $J = 8.4$ Hz, 1H), 7.58 (t, $J = 8.0$ Hz, 1H), 6.47 (s, 1H), 6.20 (s, 1H), 5.43–5.46 (m, 2H), 5.33 (s, 2H), 4.93 (d, $J = 12.0$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.20 (dd, $J = 7.2$ Hz, 4.6 Hz, 1H), 2.88 (q, $J = 7.2$ Hz, 1H), 2.11 (dd, $J = 13.2$ Hz, 4.0 Hz, 1H), 1.83 (ddd, $J = 14.4$ Hz, 13.2 Hz, 4.0 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.2 Hz, 1H), 1.12 (d, $J = 7.2$ Hz, 3H), 1.01 (s, 9H). ^{13}C -NMR (125 MHz, DMSO- d_6) δ 176.28, 172.46, 170.08, 143.79, 137.55, 131.90, 131.66, 122.77, 122.43, 121.92, 119.23, 109.66, 98.88, 92.60, 82.47, 78.45, 75.13, 73.75, 71.93, 67.29, 62.89, 48.71, 41.53, 36.51, 31.70, 28.62 (3C), 7.83. HRMS (ESI): m/z calcd for $C_{29}H_{31}BrN_3O_{10}$ $[M + H]^+$: 660.1193, found 660.1207.

10-O-(1-(2-Methylphenyl)-1H-1,2,3-triazole) ginkgolide B (5n). Following the described procedure, 39.3 mg (66%) of compound **5n** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.46 (s, 1H), 7.52–7.47 (m, 2H), 7.46–7.41 (m, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.57 (d, $J = 4.6$ Hz, 1H), 5.45 (d, $J = 12.2$ Hz, 1H), 5.35–5.33 (m, 2H), 4.97 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.2$ Hz, 1H), 4.21 (dd, $J = 7.2$, 4.7 Hz, 1H), 2.89 (q, $J = 7.0$ Hz, 1H), 2.15 (s, 3H), 2.13 (dd, $J = 13.7$, 4.5 Hz, 1H), 1.91–1.80 (m, 1H), 1.75 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.03 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.83, 173.02, 170.63, 143.35, 136.56, 133.54, 131.90, 130.45, 127.53, 126.45, 125.28, 110.16, 99.33, 93.08, 82.94, 79.01, 75.62, 74.23, 72.43, 67.83, 63.57, 49.20, 41.90, 37.01, 32.22, 29.14 (3C), 17.84, 8.32. HRMS (ESI): m/z calcd for $C_{30}H_{34}N_3O_{10}$ $[M + H]^+$: 596.2244, found 596.2249.

10-O-(1-(2-Hydroxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5o). Following the described procedure, 22.1 mg (37%) of compound **5o** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 10.59 (s, 1H), 8.51 (s, 1H), 7.60 (dd, $J = 7.9$, 1.6 Hz, 1H), 7.36 (ddd, $J = 8.2$, 7.5, 1.7 Hz, 1H), 7.12 (dd, $J = 8.2$, 1.2 Hz, 1H), 7.00 (td, $J = 7.8$, 1.3 Hz, 1H), 6.46 (s, 1H), 6.20 (s, 1H), 5.64 (d, $J = 4.7$ Hz, 1H), 5.45 (d, $J = 12.2$ Hz, 1H), 5.34–5.32 (m, 2H), 4.93 (d, $J = 12.1$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.22 (dd, $J = 7.2$, 4.5 Hz, 1H), 2.92–2.84 (m, 1H), 2.12 (dd, $J = 13.3$ Hz, 4.4 Hz, 1H), 1.84 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.3$ Hz, 4.3 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 175.74, 171.96, 169.55, 149.06, 141.97, 129.74, 124.60, 124.12, 123.73, 118.97, 116.45, 109.07, 98.23, 91.99, 81.83, 77.91, 74.66, 73.13, 71.35, 66.74, 62.61, 48.10, 40.98, 35.93, 31.15, 28.07 (3C), 7.23. HRMS (ESI): m/z calcd for $C_{29}H_{32}N_3O_{11}$ $[M + H]^+$: 598.2037, found 598.2051.

10-O-(1-(2-Cyanophenyl)-1H-1,2,3-triazole) ginkgolide B (5p). Following the described procedure, 25.5 mg (42%) of compound **5p** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.74 (s, 1H), 8.16 (dd, $J = 7.8$, 1.3 Hz, 1H), 7.98 (td, $J = 7.9$, 1.4 Hz, 1H), 7.90–7.86 (m, 1H), 7.79 (td, $J = 7.7$, 1.1 Hz, 1H), 6.49 (s, 1H), 6.20 (s, 1H), 5.48 (d, $J = 12.4$ Hz, 2H), 5.37–5.30 (m, 2H), 4.99 (d, $J = 12.3$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.22 (d, $J = 7.1$ Hz, 1H), 2.92–2.85 (m, 1H), 2.11 (dd, $J = 13.5$, 4.5 Hz, 1H), 1.86 (dt, $J = 13.7$, 7.0 Hz, 1H), 1.74 (dd, $J = 14.4$, 4.5 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.81, 172.97, 170.63, 144.21, 138.10, 135.41, 135.30, 130.92, 126.18, 124.91, 116.22, 110.16, 107.43, 99.41, 93.18, 82.97, 79.00, 75.76, 74.22, 72.41, 67.82, 63.48, 49.20, 42.04, 37.01, 32.22, 29.13 (3C), 8.35. HRMS (ESI): m/z calcd for $C_{30}H_{31}N_4O_{10}$ $[M + H]^+$: 607.2040, found 607.2050.

10-O-(1-(3-Methylphenyl)-1H-1,2,3-triazole) ginkgolide B (5q). Following the described procedure, 26.8 mg (45%) of compound **5q** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.78 (s, 1H), 7.72 (t, $J = 2.6$ Hz, 1H), 7.68–7.63 (m, 1H), 7.50 (t, $J = 7.8$ Hz, 1H), 7.34 (d, $J = 7.6$ Hz, 1H), 6.47 (s, 1H), 6.20 (s, 1H), 5.50 (d, $J = 4.5$ Hz, 1H), 5.44 (d, $J = 12.1$ Hz, 1H), 5.33 (d, $J = 4.8$ Hz, 2H), 4.93 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.22–4.18 (m, 1H), 2.88 (q, $J = 7.1$ Hz, 1H), 2.42 (s, 3H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$, 4.3 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 175.72, 171.93, 169.53, 143.06, 139.14, 135.83, 129.16, 128.93, 120.98, 120.04, 116.73,

109.08, 98.26, 92.00, 81.87, 77.89, 74.53, 73.16, 71.35, 66.72, 62.36, 48.11, 40.97, 35.93, 31.13, 28.04 (3C), 20.32, 7.25. HRMS (ESI): m/z calcd for $C_{30}H_{34}N_3O_{10}$ $[M + H]^+$: 596.2244, found 596.2255.

10-O-(1-(3-Isopropylphenyl)-1H-1,2,3-triazole) ginkgolide B (5r). Following the described procedure, 34.3 mg (55%) of compound **5r** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (3). 1H -NMR (600 MHz, DMSO- d_6) δ 8.81 (s, 1H), 7.75 (t, $J = 1.8$ Hz, 1H), 7.68–7.67 (m, 1H), 7.53 (t, $J = 7.9$ Hz, 1H), 7.41 (d, $J = 7.7$ Hz, 1H), 6.50 (s, 1H), 6.20 (s, 1H), 5.54 (d, $J = 4.6$ Hz, 1H), 5.45 (d, $J = 12.1$ Hz, 1H), 5.34 (d, $J = 3.4$ Hz, 2H), 4.94 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.22 (dd, $J = 7.1$ Hz, 4.5 Hz, 1H), 3.06–2.99 (m, 1H), 2.89 (q, $J = 7.0$ Hz, 1H), 2.12 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.3 Hz, 1H), 1.27 (d, $J = 6.9$ Hz, 6H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.83, 173.02, 170.63, 150.14, 144.04, 136.99, 130.39, 127.50, 122.12, 118.67, 118.27, 110.16, 99.35, 93.06, 82.94, 78.99, 75.60, 74.25, 72.44, 67.81, 63.41, 49.19, 42.04, 37.00, 33.87, 32.20, 29.11 (3C), 24.11 (2C), 8.32. HRMS (ESI): m/z calcd for $C_{32}H_{38}N_3O_{10}$ $[M + H]^+$: 624.2557, found 624.2565.

10-O-(1-(3-Ethylcarboxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5s). Following the described procedure, 17.6 mg (27%) of compound **5s** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (3). 1H -NMR (600 MHz, DMSO- d_6) δ 8.94 (s, 1H), 8.40 (s, 1H), 8.18 (dd, $J = 8.1$, 0.8 Hz, 1H), 8.08 (dd, $J = 7.8$, 0.9 Hz, 1H), 7.79 (t, $J = 8.0$ Hz, 1H), 6.49 (s, 1H), 6.21 (s, 1H), 5.48 (d, $J = 4.6$ Hz, 1H), 5.46 (d, $J = 12.2$ Hz, 1H), 5.36–5.31 (m, 2H), 4.95 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.38 (q, $J = 7.1$ Hz, 2H), 4.22 (dd, $J = 7.1$, 4.6 Hz, 1H), 2.89 (q, $J = 7.0$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.84 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.36 (t, $J = 7.1$ Hz, 3H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.81, 173.00, 170.61, 165.21, 144.41, 137.17, 132.08, 131.16, 129.77, 125.17, 122.46, 120.88, 110.16, 99.37, 93.11, 82.96, 78.98, 75.64, 74.23, 72.43, 67.80, 63.39, 61.85, 49.20, 42.04, 37.00, 32.21, 29.12 (3C), 14.59, 8.34. HRMS (ESI): m/z calcd for $C_{32}H_{36}N_3O_{12}$ $[M + H]^+$: 654.2299, found 654.2309.

10-O-(1-(3-Carboxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5t). Following the described procedure, 15.6 mg (25%) of compound **5t** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (3). 1H -NMR (600 MHz, DMSO- d_6) δ 13.45 (s, 1H), 8.94 (s, 1H), 8.38 (s, 1H), 8.16–8.14 (m, 1H), 8.11–7.99 (m, 1H), 7.76 (t, $J = 7.9$ Hz, 1H), 6.47 (s, 1H), 6.21 (s, 1H), 5.47–5.44 (m, 2H), 5.35–5.28 (m, 2H), 4.94 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.1$ Hz, 4.6 Hz, 1H), 2.89 (q, $J = 7.1$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.84 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.81, 173.01, 170.62, 166.75, 144.21, 136.99, 133.01, 130.95, 129.88, 124.72, 122.30, 120.85, 110.07, 99.24, 92.99, 82.94, 78.93, 75.54, 74.21, 72.38, 67.74, 63.34, 49.20, 42.04, 36.74, 32.20, 29.12 (3C), 8.26. HRMS (ESI): m/z calcd for $C_{30}H_{32}N_3O_{12}$ $[M + H]^+$: 626.1986, found 626.1998.

10-O-(1-(4-Methylphenyl)-1H-1,2,3-triazole) ginkgolide B (5u). Following the described procedure, 31.5 mg (53%) of compound **5u** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (3). 1H -NMR (600 MHz, DMSO- d_6) δ 8.75 (s, 1H), 7.76 (d, $J = 8.4$ Hz, 2H), 7.42 (d, $J = 8.1$ Hz, 2H), 6.46 (s, 1H), 6.20 (s, 1H), 5.53 (d, $J = 4.6$ Hz, 1H), 5.44 (d, $J = 12.2$ Hz, 1H), 5.33 (d, $J = 3.2$ Hz, 2H), 4.92 (d, $J = 12.1$ Hz, 1H), 4.63 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.2$, 4.6 Hz, 1H), 2.88 (q, $J = 7.0$ Hz, 1H), 2.39 (s, 3H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.3 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 175.72, 171.94, 169.52, 142.94, 137.81, 133.34, 129.57 (2C), 120.81, 119.40 (2C), 109.01, 98.21, 91.97, 81.84, 77.84, 74.37, 73.03, 71.26, 66.65, 62.28, 47.99, 40.81, 35.83, 30.92, 28.04 (3C), 19.99, 7.01. HRMS (ESI): m/z calcd for $C_{30}H_{34}N_3O_{10}$ $[M + H]^+$: 596.2244, found 596.2251.

10-O-(1-(4-Methoxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5v). Following the described procedure, 20.8 mg (34%) of compound **5v** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (3). 1H -NMR (600 MHz, DMSO- d_6) δ 8.69 (s, 1H), 7.78 (d, $J = 9.0$ Hz, 2H), 7.15 (d, $J = 9.1$ Hz, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.57 (d, $J = 4.6$ Hz, 1H), 5.44 (d, $J = 12.1$ Hz, 1H), 5.33 (s, 2H), 4.92 (d, $J = 12.1$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.21 (dd, $J = 7.2$, 4.6 Hz, 1H), 3.84 (s, 3H), 2.88 (q, $J = 7.1$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$

Hz, 4.3 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.83, 173.02, 170.63, 159.92, 144.00, 130.31, 122.40 (2C), 121.94, 115.42 (2C), 110.16, 99.34, 93.08, 82.93, 79.00, 75.43, 74.13, 72.34, 67.75, 63.27, 55.84, 49.09, 41.96, 36.94, 32.01, 28.95 (3C), 8.19. HRMS (ESI): m/z calcd for $\text{C}_{30}\text{H}_{34}\text{N}_3\text{O}_{11}$ $[\text{M} + \text{H}]^+$: 612.2193, found 612.2205.

10-O-(1-(4-Fluorophenyl)-1H-1,2,3-triazole) ginkgolide B (5w). Following the described procedure, 13.5 mg (22%) of compound **5w** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 8.69 (s, 1H), 7.93–7.89 (m, 2H), 7.49–7.44 (m, 2H), 6.64 (s, 1H), 6.19 (s, 1H), 5.63 (d, $J = 4.5$ Hz, 1H), 5.46 (d, $J = 12.2$ Hz, 1H), 5.37 (d, $J = 4.1$ Hz, 1H), 5.31 (s, 1H), 4.97 (d, $J = 12.2$ Hz, 1H), 4.65 (d, $J = 7.1$ Hz, 1H), 4.24 (dd, $J = 7.1$ Hz, 4.4 Hz, 1H), 2.91 (q, $J = 7.1$ Hz, 1H), 2.14 (dd, $J = 13.5$ Hz, 4.5 Hz, 1H), 1.86 (td, $J = 13.9$ Hz, 4.2 Hz, 1H), 1.75 (dd, $J = 14.4$ Hz, 4.5 Hz, 1H), 1.15 (d, $J = 7.1$ Hz, 3H), 1.03 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 177.01, 172.98, 170.81, 162.28 (d, $J_{\text{C-F}} = 246.4$ Hz), 144.27, 133.33 (d, $J_{\text{C-F}} = 2.5$ Hz), 123.18 (d, $J_{\text{C-F}} = 8.9$ Hz, 2C), 122.14, 117.30 (d, $J_{\text{C-F}} = 23.3$ Hz, 2C), 110.18, 99.41, 93.08, 82.95, 79.16, 75.63, 74.28, 72.44, 67.85, 63.41, 49.21, 42.02, 36.95, 32.11, 29.03 (3C), 7.94. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{31}\text{FN}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 600.1993, found 600.2010.

10-O-(1-(4-Bromophenyl)-1H-1,2,3-triazole) ginkgolide B (5x). Following the described procedure, 18.5 mg (28%) of compound **5x** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 8.83 (s, 1H), 7.88–7.85 (m, 2H), 7.85–7.81 (m, 2H), 6.47 (s, 1H), 6.20 (s, 1H), 5.47 (d, $J = 4.6$ Hz, 1H), 5.45 (d, $J = 12.2$ Hz, 1H), 5.33 (d, $J = 4.1$ Hz, 1H), 4.93 (d, $J = 12.1$ Hz, 1H), 4.63 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.1$ Hz, 4.6 Hz, 1H), 2.88 (q, $J = 7.1$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.3 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.80, 172.99, 170.60, 144.39, 136.14, 133.35 (2C), 122.63 (2C), 122.20, 122.09, 110.16, 99.36, 93.10, 82.96, 78.97, 75.65, 74.23, 72.42, 67.79, 63.33, 49.02, 41.91, 36.81, 32.10, 28.98 (3C), 8.26. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{31}\text{BrN}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 660.1193, found 660.1208.

10-O-(1-(4-Trifluoromethylphenyl)-1H-1,2,3-triazole) ginkgolide B (5y). Following the described procedure, 20.1 mg (31%) of compound **5y** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 8.95 (s, 1H), 8.15 (d, $J = 8.4$ Hz, 2H), 8.02 (d, $J = 8.6$ Hz, 2H), 6.47 (s, 1H), 6.21 (s, 1H), 5.47 (d, $J = 12.2$ Hz, 1H), 5.45 (d, $J = 4.6$ Hz, 1H), 5.35–5.32 (m, 2H), 4.95 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.1$ Hz, 4.6 Hz, 1H), 2.89 (q, $J = 7.1$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.84 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.81, 172.98, 170.61, 144.59, 139.72, 129.34 (q, $J_{\text{C-F}} = 32.1$ Hz), 127.78 (q, $J_{\text{C-F}} = 3.6$ Hz, 2C), 124.27 (q, $J = 270.5$ Hz), 122.50, 121.21 (2C), 110.16, 99.38, 93.12, 82.97, 78.97, 75.68, 74.24, 72.42, 67.80, 63.39, 49.19, 42.04, 37.01, 32.21, 29.12 (3C), 8.34. HRMS (ESI): m/z calcd for $\text{C}_{30}\text{H}_{31}\text{F}_3\text{N}_3\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 650.1962, found 650.1967.

10-O-(1-(4-Nitrophenyl)-1H-1,2,3-triazole) ginkgolide B (5z). Following the described procedure, 21.9 mg (35%) of compound **5z** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 9.00 (s, 1H), 8.49–8.47 (m, 2H), 8.23–8.20 (m, 2H), 6.47 (s, 1H), 6.20 (d, $J = 6.2$ Hz, 1H), 5.46 (t, $J = 12.2$ Hz, 1H), 5.40 (d, $J = 4.6$ Hz, 1H), 5.36–5.32 (m, 2H), 4.95 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.1$ Hz, 4.6 Hz, 1H), 2.93–2.84 (m, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.84 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.79, 172.97, 170.60, 147.38, 144.82, 141.16, 126.13 (2C), 122.76, 121.30 (2C), 110.16, 99.39, 93.14, 82.98, 78.96, 75.74, 74.23, 72.41, 67.79, 63.37, 49.19, 42.04, 37.01, 32.22, 29.13 (3C), 8.35. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{31}\text{N}_4\text{O}_{12}$ $[\text{M} + \text{H}]^+$: 627.1938, found 627.1948.

10-O-(1-(4-Methylcarboxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5aa). Following the described procedure, 18.5 mg (29%) of compound **5aa** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). $^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 8.94 (s, 1H), 8.20–8.16 (m, 2H), 8.09–8.06 (m, 2H), 6.47 (s, 1H), 6.21 (s, 1H), 5.46 (d, $J = 12.2$ Hz, 1H), 5.42 (d, $J = 4.6$ Hz, 1H), 5.36–5.28 (m, 2H), 4.94 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.1$ Hz, 4.6 Hz, 1H), 3.90 (s, 3H), 2.88 (q, $J = 7.1$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.84 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$) δ 176.80, 172.98, 170.60, 165.79, 144.58, 140.11, 131.53 (2C), 130.08, 122.40, 120.57 (2C), 110.16, 99.38, 93.12, 82.97,

78.97, 75.71, 74.23, 72.42, 67.79, 63.41, 52.64, 49.03, 42.04, 36.70, 32.12, 28.90 (3C), 8.29. HRMS (ESI): m/z calcd for $C_{31}H_{34}N_3O_{12}$ $[M + H]^+$: 640.2142, found 640.2154.

10-O-(1-(4-Carboxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5bb). Following the described procedure, 16.3 mg (26%) of compound **5bb** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.88 (s, 1H), 8.16 (d, $J = 8.4$ Hz, 2H), 8.16 (d, $J = 8.4$ Hz, 2H), 6.50 (s, 1H), 6.19 (s, 1H), 5.49–5.44 (m, 2H), 5.35–5.32 (m, 2H), 4.94 (d, $J = 12.0$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.21 (dd, $J = 7.2$ Hz, 4.2 Hz, 1H), 2.88 (q, $J = 7.2$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.84, 172.98, 170.50, 166.86, 144.40, 139.78, 131.60 (2C), 131.29, 122.20, 120.28 (2C), 109.95, 99.28, 93.09, 82.95, 79.01, 75.55, 74.25, 72.32, 67.76, 63.29, 49.16, 41.92, 36.87, 32.10, 29.11 (3C), 8.25. HRMS (ESI): m/z calcd for $C_{30}H_{32}N_3O_{12}$ $[M + H]^+$: 626.1986, found 626.1998.

10-O-(1-(3,5-Dimethoxyphenyl)-1H-1,2,3-triazole) ginkgolide B (5cc). Following the described procedure, 22.5 mg (35%) of compound **5cc** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.79 (s, 1H), 7.05 (d, $J = 2.4$ Hz, 2H), 6.63 (t, $J = 2.4$ Hz, 1H), 6.52 (s, 1H), 6.18 (s, 1H), 5.52 (s, $J = 4.2$ Hz, 1H), 5.43 (d, $J = 12.0$ Hz, 1H), 5.34 (d, $J = 4.2$ Hz, 1H), 5.32 (s, 1H), 4.92 (d, $J = 12.0$ Hz, 1H), 4.63 (d, $J = 7.2$ Hz, 1H), 4.22 (dd, $J = 7.2$ Hz, 4.2 Hz, 1H), 3.84 (s, 6H), 2.88 (q, $J = 7.2$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$, 4.2 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.87, 173.00, 170.66, 161.70 (2C), 144.08, 138.40, 122.15, 110.17, 100.86, 99.37, 98.98 (2C), 93.05, 82.94, 79.03, 75.60, 74.26, 72.43, 67.81, 63.37, 56.21 (2C), 49.20, 42.03, 36.98, 32.17, 29.09 (3C), 8.31. HRMS (ESI): m/z calcd for $C_{31}H_{36}N_3O_{12}$ $[M + H]^+$: 642.2299, found 642.2308.

10-O-(1-(3-Chloro-4-fluorophenyl)-1H-1,2,3-triazole) ginkgolide B (5dd). Following the described procedure, 29.2 mg (46%) of compound **5dd** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.83 (s, 1H), 8.20–8.18 (m, 1H), 8.00–7.88 (m, 1H), 7.75–7.60 (m, 1H), 6.48 (s, 1H), 6.20 (s, 1H), 5.46–5.41 (m, 2H), 5.33 (s, 2H), 4.93 (d, $J = 12.0$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.23–4.17 (m, 1H), 2.88 (q, $J = 7.2$ Hz, 1H), 2.11 (dd, $J = 13.4$ Hz, 4.4 Hz, 1H), 1.83 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.73 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). HRMS (ESI): m/z calcd for $C_{29}H_{30}ClF_2N_3O_{10}$ $[M + H]^+$: 634.1604, found 634.1619.

10-O-(1-(3-Pyridinyl)-1H-1,2,3-triazole) ginkgolide B (5ee). Following the described procedure, 45.7 mg (67%) of compound **5ee** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 9.13 (d, $J = 2.5$ Hz, 1H), 8.88 (s, 1H), 8.71 (d, $J = 4.8$ Hz, 1H), 8.35–8.30 (m, 1H), 7.68 (dd, $J = 8.4$, 4.8 Hz, 1H), 6.49 (s, 1H), 6.21 (s, 1H), 5.49 (d, $J = 4.8$ Hz, 1H), 5.47 (d, $J = 12.0$ Hz, 1H), 5.34 (d, $J = 3.2$ Hz, 2H), 4.95 (d, $J = 12.1$ Hz, 1H), 4.64 (d, $J = 7.1$ Hz, 1H), 4.21 (dd, $J = 7.1$ Hz, 4.5 Hz, 1H), 2.88 (q, $J = 7.0$ Hz, 1H), 2.12 (dd, $J = 13.5$ Hz, 4.5 Hz, 1H), 1.85 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.74 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.03 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.80, 172.99, 170.59, 150.41, 144.45, 141.84, 133.59, 128.59, 125.10, 122.47, 110.07, 99.32, 92.92, 82.84, 78.99, 75.45, 73.96, 72.07, 67.61, 63.29, 48.94, 42.04, 36.71, 31.75, 29.12 (3C), 8.16. HRMS (ESI): m/z calcd for $C_{28}H_{31}N_4O_{10}$ $[M + H]^+$: 583.2040, found 583.2056.

10-O-(1-Benzyl-1H-1,2,3-triazole) ginkgolide B (5ff). Following the described procedure, 42.8 mg (72%) of compound **5ff** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.17 (s, 1H), 7.41–7.30 (m, 5H), 6.47 (s, 1H), 6.17 (s, 1H), 5.64 (d, $J = 4.4$ Hz, 1H), 5.61 (s, 2H), 5.35–5.31 (m, 2H), 5.27 (s, 1H), 4.84 (d, $J = 12.1$ Hz, 1H), 4.62 (d, $J = 7.2$ Hz, 1H), 4.17 (dd, $J = 7.1$ Hz, 4.5 Hz, 1H), 2.86 (q, $J = 7.0$ Hz, 1H), 2.09 (dd, $J = 12.9$ Hz, 3.9 Hz, 1H), 1.77 (td, $J = 13.8$ Hz, 4.2 Hz, 1H), 1.70 (dd, $J = 14.4$ Hz, 4.4 Hz, 1H), 1.12 (d, $J = 7.1$ Hz, 3H), 0.98 (s, 9H). ^{13}C -NMR (150 MHz, DMSO- d_6) δ 176.83, 172.99, 170.62, 143.50, 136.17, 129.26 (2C), 128.69, 128.48 (2C), 123.01, 109.77, 98.98, 92.78, 82.56, 78.85, 75.51, 74.03, 72.28, 67.54, 63.16, 53.19, 48.92, 41.92, 36.77, 31.99, 28.81 (3C), 8.15. HRMS (ESI): m/z calcd for $C_{30}H_{34}N_3O_{10}$ $[M + H]^+$: 596.2244, found 596.2266.

10-O-(((Anthracen-2-yloxy)methyl)-1H-1,2,3-triazole) ginkgolide B (5gg). Following the described procedure, 43.5 mg (70%) of compound **5gg** were obtained from 46.2 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide B (**3**). 1H -NMR (600 MHz, DMSO- d_6) δ 8.22 (s, 1H), 7.93 (dd, J

= 7.8 Hz, 1.3 Hz, 1H), 7.73 (td, $J = 7.7$ Hz, 1.4 Hz, 1H), 7.58 (td, $J = 7.7$ Hz, 1.2 Hz, 1H), 7.38 (dd, $J = 7.9$ Hz, 1.1 Hz, 1H), 6.45 (s, 1H), 6.17 (s, 1H), 5.83 (s, 2H), 5.58 (d, $J = 4.6$ Hz, 1H), 5.36 (d, $J = 12.2$ Hz, 1H), 5.31 (d, $J = 3.9$ Hz, 1H), 5.28 (s, 1H), 4.86 (d, $J = 12.1$ Hz, 1H), 4.61 (d, $J = 7.2$ Hz, 1H), 4.17 (dd, $J = 7.2$ Hz, 4.2 Hz, 1H), 4.03 (q, $J = 7.1$ Hz, 1H), 2.87 (q, $J = 7.1$ Hz, 1H), 2.50 (s, 2H), 2.09 (dd, $J = 13.0$ Hz, 4.1 Hz, 1H), 1.99 (s, 2H), 1.83–1.68 (m, 2H), 1.18 (t, $J = 7.1$ Hz, 2H), 1.12 (d, $J = 7.1$ Hz, 3H), 0.98 (s, 9H). ^{13}C NMR (150 MHz, DMSO- d_6) δ 176.91, 172.97, 170.70, 143.52, 138.80, 134.36, 133.90, 130.22, 129.89, 124.13, 117.45, 111.79, 110.15, 99.32, 82.87, 79.06, 75.62, 74.19, 72.42, 67.81, 63.54, 60.34, 51.71, 49.15, 42.02, 36.92, 32.12, 29.04(3C), 8.25. HRMS (ESI): m/z calcd for $\text{C}_{31}\text{H}_{32}\text{N}_4\text{O}_{10}$ $[\text{M} + \text{H}]^+$: 621.2198, found 621.2170.

10-O-(1-Phenyl-1H-1,2,3-triazole) ginkgolide A (5'a). Following the described procedure, 36.2 mg (64%) of compound **5'a** were obtained from 44.6 mg (0.1 mmol) of 10-O-propargylated ginkgolide A (**3'**). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.51 (s, 1H), 7.48 (s, 2H), 7.43 (d, $J = 16.7$ Hz, 2H), 6.45–6.32 (m, 1H), 6.15 (s, 1H), 5.36 (d, $J = 12.0$ Hz, 1H), 5.23 (s, 1H), 4.95 (d, $J = 4.0$ Hz, 1H), 4.89 (d, $J = 11.9$ Hz, 1H), 4.83 (dd, $J = 8.4$ Hz, 7.3 Hz, 1H), 3.85–3.71 (m, 2H), 3.62–3.56 (m, 1H), 3.17 (d, $J = 5.3$ Hz, 1H), 2.95 (q, $J = 7.1$ Hz, 1H), 2.75 (dd, $J = 15.1$ Hz, 7.2 Hz, 1H), 2.04 (dd, $J = 13.6$ Hz, 5.0 Hz, 1H), 2.01–1.91 (m, 2H), 1.91–1.80 (m, 2H), 1.79–1.70 (m, 3H), 1.70–1.63 (m, 1H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, DMSO- d_6) δ 176.98, 173.22, 171.05, 144.45, 130.41(2C), 122.91, 120.67(2C), 110.14, 100.81, 87.96, 86.50, 85.31, 75.74, 68.63, 66.81, 66.19, 63.35, 49.16, 36.78, 36.45, 33.62, 32.19, 29.17(3C), 23.75, 8.59. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{31}\text{N}_3\text{O}_9$ $[\text{M} + \text{H}]^+$: 566.2133, found 566.2111.

10-O-(1-(2-Methylphenyl)-1H-1,2,3-triazole) ginkgolide A (5'n). Following the described procedure, 40.0 mg (69%) of compound **5'n** were obtained from 44.6 mg (0.1 mmol) of 10-O-propargylated ginkgolide A (**3'**). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.51 (s, 1H), 7.52–7.48 (m, 2H), 7.44 (dd, $J = 2.2$, 1.0 Hz, 2H), 6.40 (s, 1H), 6.15 (s, 1H), 5.40–5.33 (m, 2H), 5.23 (s, 1H), 4.95 (d, $J = 4.1$ Hz, 1H), 4.89 (d, $J = 11.9$ Hz, 1H), 4.83 (d, $J = 1.1$ Hz, 1H), 3.82–3.75 (m, 2H), 3.60 (s, 1H), 3.17 (d, $J = 5.3$ Hz, 1H), 2.95 (d, $J = 7.2$ Hz, 1H), 2.75 (dd, $J = 15.1$ Hz, 7.2 Hz, 1H), 2.15 (s, 3H), 1.97 (s, 1H), 1.78–1.69 (m, 3H), 1.13 (d, $J = 7.1$ Hz, 3H), 1.02 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, DMSO- d_6) δ 176.97, 173.19, 171.05, 143.65, 136.71, 133.55, 131.87, 130.34, 127.50, 126.51, 126.03, 110.13, 100.79, 97.64, 87.94, 86.50, 85.35, 75.74, 67.49, 63.53, 49.07, 41.66, 40.47, 36.78, 32.20, 29.16(3C), 17.87, 8.59. HRMS (ESI): m/z calcd for $\text{C}_{30}\text{H}_{33}\text{N}_3\text{O}_9$ $[\text{M} + \text{H}]^+$: 580.2197, found 580.2266.

10-O-(1-(2-Cyanophenyl)-1H-1,2,3-triazole) ginkgolide A (5'p). Following the described procedure, 34.3 mg (58%) of compound **5'p** were obtained from 44.6 mg (0.1 mmol) of 10-O-propargylated ginkgolide A (**3'**). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.82 (s, 1H), 8.16 (dd, $J = 7.9$, 1.5 Hz, 1H), 7.98 (td, $J = 7.9$, 1.5 Hz, 1H), 7.91 (dd, $J = 8.2$, 1.2 Hz, 1H), 7.79 (td, $J = 7.7$, 1.2 Hz, 1H), 6.41 (s, 1H), 6.16 (s, 1H), 5.41 (d, $J = 11.9$ Hz, 1H), 5.39–5.35 (m, 2H), 5.26 (s, 1H), 4.97–4.87 (m, 2H), 4.82 (t, $J = 7.8$ Hz, 1H), 2.95 (q, $J = 7.1$ Hz, 1H), 2.79–2.72 (m, 1H), 1.40 (s, 3H), 1.13 (d, $J = 7.2$ Hz, 3H), 1.04 (s, 9H). $^{13}\text{C-NMR}$ (150 MHz, DMSO- d_6) δ 174.85, 171.03, 168.75, 142.36, 133.25, 133.10, 128.73, 128.69, 124.10, 123.44, 110.75, 108.04, 108.01, 98.77, 95.53, 85.83, 84.40, 83.30, 73.77, 66.57, 64.74, 61.33, 47.05, 39.68, 34.68, 34.37, 31.51(3C), 8.07. HRMS (ESI): m/z calcd for $\text{C}_{30}\text{H}_{30}\text{N}_4\text{O}_9$ $[\text{M} + \text{H}]^+$: 591.2093, found 591.2062.

10-O-(1-Benzyl-1H-1,2,3-triazole) ginkgolide A (5'ff). Following the described procedure, 39.4 mg (68%) of compound **5'ff** were obtained from 44.6 mg (0.1 mmol) of 10-O-propargylated ginkgolide A (**3'**). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.25 (s, 1H), 7.38 (dd, $J = 8.0$, 6.4 Hz, 2H), 7.34–7.22 (m, 3H), 6.40 (s, 1H), 6.12 (s, 1H), 5.61 (d, $J = 6.9$ Hz, 2H), 5.24 (d, $J = 11.6$ Hz, 1H), 5.16 (s, 1H), 4.92 (d, $J = 4.0$ Hz, 1H), 4.82 (t, $J = 7.8$ Hz, 1H), 4.76 (d, $J = 11.6$ Hz, 1H), 4.03 (q, $J = 7.1$ Hz, 1H), 2.94 (d, $J = 7.2$ Hz, 1H), 2.65 (dd, $J = 15.1$ Hz, 7.2 Hz, 1H), 2.50 (p, $J = 1.8$ Hz, 3H), 2.05–1.99 (m, 1H), 1.99 (s, 1H), 1.90 (d, $J = 4.4$ Hz, 1H), 1.84 (dd, $J = 15.1$, 8.4 Hz, 1H), 1.70 (dd, $J = 14.1$, 4.7 Hz, 1H), 1.17 (t, $J = 7.1$ Hz, 1H), 1.12 (dd, $J = 7.1$, 4.0 Hz, 3H), 0.98 (d, $J = 3.6$ Hz, 9H). $^{13}\text{C-NMR}$ (150 MHz, DMSO- d_6) δ 177.20, 173.13, 171.32, 136.27, 129.28(2C), 128.74, 128.39, 124.82, 110.16, 110.03, 101.11, 88.10, 86.53, 85.77, 75.61, 68.76, 66.93, 63.50, 63.40, 53.55, 53.35, 49.15, 40.86, 36.82, 32.04, 29.02(3C), 8.71. HRMS (ESI): m/z calcd for $\text{C}_{30}\text{H}_{33}\text{N}_3\text{O}_9$ $[\text{M} + \text{H}]^+$: 580.2297, found 580.2267.

10-O-(((Anthracen-2-yloxy)methyl)-1H-1,2,3-triazole) ginkgolide A (5'gg). Following the described procedure, 36.9 mg (61%) of compound **5'gg** were obtained from 44.6 mg (0.1 mmol) of

10-*O*-propargylated ginkgolide A (**3'**). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.29 (s, 1H), 7.92 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.82–7.69 (m, 1H), 7.57 (td, *J* = 7.7, 1.2 Hz, 1H), 7.44–7.26 (m, 1H), 6.40 (s, 1H), 6.13 (s, 1H), 5.83 (s, 2H), 5.27 (d, *J* = 11.8 Hz, 1H), 5.18 (s, 1H), 4.90 (d, *J* = 4.0 Hz, 1H), 4.83 (dd, *J* = 8.2 Hz, 7.3 Hz, 1H), 4.78 (d, *J* = 11.7 Hz, 1H), 4.03 (q, *J* = 7.1 Hz, 19H), 2.95 (q, *J* = 7.2 Hz, 1H), 2.66 (dd, *J* = 15.2 Hz, 7.2 Hz, 1H), 2.51 (p, *J* = 1.8 Hz, 4H), 1.90–1.82 (m, 2H), 1.72 (dd, *J* = 14.1 Hz, 4.7 Hz, 2H), 1.40 (s, 3H), 1.13 (d, *J* = 7.2 Hz, 3H), 0.99 (d, *J* = 5.3 Hz, 9H). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 176.93, 173.14, 170.81, 143.66, 139.26, 134.29, 133.85, 129.91, 129.68, 125.44, 117.45, 111.68, 110.09, 100.82, 87.90, 86.50, 85.33, 75.74, 68.63, 66.81, 63.47, 60.22, 51.47, 49.03, 40.89, 36.40, 32.14, 29.10(3C), 8.56. HRMS (ESI): *m/z* calcd for C₃₁H₃₂N₄O₉ [M + H]⁺: 605.2249, found 605.2219.

10-*O*-(1-Phenyl-1*H*-1,2,3-triazole) ginkgolide C (**5''a**). Following the described procedure, 31.1 mg (52%) of compound **5''a** were obtained from 47.8 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide C (**3''**). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.83 (s, 1H), 7.88 (dt, *J* = 7.9, 1.1 Hz, 2H), 7.63 (dd, *J* = 8.8, 7.2 Hz, 3H), 7.53 (t, *J* = 7.4 Hz, 1H), 6.48 (s, 1H), 6.23 (s, 1H), 5.64 (t, *J* = 5.3 Hz, 2H), 5.46 (d, *J* = 12.2 Hz, 1H), 5.32 (s, 1H), 4.99 (d, *J* = 4.2 Hz, 2H), 4.63 (d, *J* = 7.0 Hz, 1H), 4.32 (s, 1H), 4.17 (dd, *J* = 7.0 Hz, 4.6 Hz, 1H), 2.98–2.78 (m, 1H), 1.99 (s, 1H), 1.57 (d, *J* = 12.5 Hz, 1H), 1.43–1.35 (m, 2H), 1.32–1.27 (m, 1H), 1.24 (s, 2H), 1.17 (t, *J* = 7.1 Hz, 1H), 1.13 (d, *J* = 7.1 Hz, 4H), 1.10 (s, 3H), 1.07 (s, 9H). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 176.79, 172.94, 170.86, 162.28, 144.14, 136.89, 130.50, 122.14, 120.73, 110.04, 99.08, 93.14, 82.93, 75.47, 74.09, 67.05, 64.03, 63.52, 60.84, 49.35, 42.03, 35.12, 32.08, 19.09(3C), 14.32, 8.34. HRMS (ESI): *m/z* calcd for C₂₉H₃₁N₃O₁₁ [M + H]⁺: 598.2039, found 598.2003.

10-*O*-(1-(2-Methylphenyl)-1*H*-1,2,3-triazole) ginkgolide C (**5''n**). Following the described procedure, 28.7 mg (47%) of compound **5''n** were obtained from 47.8 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide C (**3''**). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.47 (s, 1H), 7.50 (d, *J* = 2.2 Hz, 2H), 7.44 (d, *J* = 1.4 Hz, 2H), 6.48 (s, 1H), 6.23 (s, 1H), 5.68 (d, *J* = 4.7 Hz, 1H), 5.66 (dd, *J* = 6.2 Hz, 2.5 Hz, 1H), 5.49–5.43 (m, 1H), 5.32 (s, 1H), 5.02–5.00 (m, 2H), 5.00–4.96 (m, 1H), 4.65–4.61 (m, 1H), 4.17 (dd, *J* = 7.0 Hz, 4.7 Hz, 1H), 2.86 (d, *J* = 7.1 Hz, 1H), 2.16 (s, 3H), 1.13 (d, *J* = 7.1 Hz, 4H), 1.10 (d, *J* = 3.7 Hz, 6H), 1.08 (s, 9H). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 176.81, 172.95, 170.89, 143.24, 136.51, 133.52, 131.93, 130.49, 127.57, 126.41, 125.27, 110.03, 99.05, 93.12, 82.92, 79.36, 75.41, 74.07, 69.35, 67.06, 64.05, 60.27, 49.38, 42.03, 32.10, 21.23(3C), 17.86, 8.34. HRMS (ESI): *m/z* calcd for C₃₀H₃₃N₃O₁₁ [M + H]⁺: 612.2195, found 612.2157.

10-*O*-(1-(2-Cyanophenyl)-1*H*-1,2,3-triazole) ginkgolide C (**5''p**). Following the described procedure, 24.3 mg (39%) of compound **5''p** were obtained from 47.8 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide C (**3''**). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.78 (s, 1H), 8.17 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.99 (td, *J* = 7.8 Hz, 1.5 Hz, 1H), 7.88 (dd, *J* = 8.2 Hz, 1.1 Hz, 1H), 7.79 (td, *J* = 7.7 Hz, 1.1 Hz, 1H), 6.48 (s, 1H), 6.23 (s, 1H), 5.64 (d, *J* = 6.1 Hz, 1H), 5.60 (d, *J* = 4.7 Hz, 1H), 5.49 (d, *J* = 12.4 Hz, 1H), 5.32 (s, 1H), 5.03 (d, *J* = 12.4 Hz, 1H), 5.01 (d, *J* = 4.2 Hz, 1H), 4.63 (d, *J* = 7.0 Hz, 1H), 4.17 (dd, *J* = 7.0 Hz, 4.7 Hz, 1H), 3.97 (ddd, *J* = 12.5 Hz, 6.1 Hz, 4.2 Hz, 1H), 2.86 (q, *J* = 7.1 Hz, 1H), 1.57 (d, *J* = 12.5 Hz, 1H), 1.13 (d, *J* = 7.1 Hz, 3H), 1.08 (s, 9H). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 176.78, 172.90, 170.87, 143.98, 135.47, 126.10, 124.92, 116.26, 110.05, 107.36, 99.11, 93.18, 82.95, 79.34, 75.46, 74.18, 74.07, 67.04, 64.02, 63.40, 60.25, 49.37, 42.03, 32.10, 27.01, 22.55, 21.24(3C), 8.35. HRMS (ESI): *m/z* calcd for C₃₀H₃₀N₄O₁₁ [M + H]⁺: 623.1991, found 623.1956.

10-*O*-(1-Benzyl-1*H*-1,2,3-triazole) ginkgolide C (**5''ff**). Following the described procedure, 26.9 mg (44%) of compound **5''ff** were obtained from 47.8 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide C (**3''**). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.19 (s, 1H), 7.40–7.37 (m, 2H), 7.35–7.32 (m, 3H), 6.46 (s, 1H), 6.20 (s, 1H), 5.73 (s, 1H), 5.62 (s, 3H), 5.35 (d, *J* = 12.2 Hz, 1H), 5.25 (s, 1H), 4.97 (d, *J* = 4.2 Hz, 1H), 4.87 (d, *J* = 12.2 Hz, 1H), 4.61 (d, *J* = 7.2 Hz, 1H), 4.13 (d, *J* = 5.7 Hz, 1H), 3.90 (d, *J* = 11.4 Hz, 1H), 2.84 (q, *J* = 7.1 Hz, 1H), 1.55 (dd, *J* = 12.5 Hz, 5.2 Hz, 1H), 1.17 (t, *J* = 7.1 Hz, 3H), 1.12 (d, *J* = 7.1 Hz, 4H), 1.10–1.09 (m, 2H), 1.03 (s, 9H). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 176.81, 172.93, 170.87, 143.32, 136.15, 129.29(2C), 128.75, 128.56, 123.60, 110.01, 98.96, 93.02, 82.83, 79.33, 75.34, 74.01, 67.04, 64.00, 63.56, 60.27, 53.51, 49.30, 42.03, 32.04, 29.07, 21.23(3C), 8.27. HRMS (ESI): *m/z* calcd for C₃₀H₃₃N₄O₁₁ [M + H]⁺: 612.2195, found 612.2156.

10-*O*-(((Anthracen-2-yloxy)methyl)-1*H*-1,2,3-triazole) ginkgolide C (**5''gg**). Following the described procedure, 32.5 mg (51%) of compound **5''gg** were obtained from 47.8 mg (0.1 mmol) of 10-*O*-propargylated ginkgolide C (**3''**). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.25 (s, 1H), 7.93 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.74 (td, *J* = 7.7 Hz, 1.4 Hz, 1H), 7.58 (td, *J* = 7.7 Hz, 1.2 Hz, 1H), 7.40 (dd, *J* = 7.8 Hz, 1.1 Hz, 1H), 6.46 (s, 1H), 6.20 (s, 1H), 5.84 (s, 2H), 5.70 (d, *J* = 4.8 Hz, 1H), 5.62 (d, *J* = 6.1 Hz, 1H), 5.37 (d, *J* = 12.2 Hz, 1H), 5.26 (s, 1H), 4.98 (d, *J* = 4.2 Hz, 1H), 4.90 (d, *J* = 12.1 Hz, 1H), 4.61 (d, *J* = 7.0 Hz, 1H), 4.13 (dd, *J* = 7.1 Hz, 4.4 Hz, 1H), 3.90 (dt, *J* = 12.4 Hz, 4.7 Hz, 1H), 2.84 (q, *J* = 7.0 Hz, 1H), 2.50 (s, 3H), 1.55 (d, *J* = 12.5 Hz, 1H), 1.18 (t, *J* = 7.1 Hz, 3H), 1.12 (d, *J* = 7.2 Hz, 3H), 1.04 (s, 9H). ¹³C NMR (150 MHz, DMSO-*d*₆) δ 176.83, 172.94, 170.92, 143.37, 138.90, 134.36, 133.88, 130.11, 129.85, 124.19, 117.47, 111.82, 110.02, 98.99, 82.84, 79.33, 75.38, 74.15, 74.01, 67.05, 64.01, 63.53, 60.27, 51.69, 49.33, 42.03, 32.04, 21.22 (3C), 8.28. HRMS (ESI): *m/z* calcd for C₃₁H₃₂N₄O₁₁ [M + H]⁺: 637.2148, found 637.2117

3.2. Antiplatelet Aggregation Activity Assay

The *in vitro* antiplatelet aggregation activity of the newly synthesized 10-substituted 1,2,3-triazole-ginkgolide derivatives was tested by the method of Born [26]. Blood samples (2 mL) from male New Zealand rabbits (2–2.5 kg body weight) were drawn into vacutainer tubes containing 200 µL of 3.2% sodium citrate. Platelet-rich plasma (PRP) was prepared by centrifuging the blood at 250× *g* for 10 min at 4 °C. The PRP was diluted with platelet-poor plasma obtained by further centrifuging at 3000× *g* for 10 min. The remaining blood was further centrifuged at 1600× *g* for 5 min to obtain platelet-poor plasma (PPP) as control group. Platelet aggregation was induced by PAF (10 nM) after incubating platelets with different concentrations of samples, and the maximum rate of platelet aggregation (RPA%) within 5 min was measured with a Helena Platelet aggregometer instrument [27]. The inhibition ratio was calculated according to the following formula:

$$\text{Inhibition ratio (\%)} = (1 - (\text{RPA\% of test group}) / (\text{RPA\% of control group})) \times 100\%$$

In primary screening, the activities were expressed directly as inhibition ratio at 50 nM concentration. The activity of the most active ginkgolide-1,2,3-triazole derivatives was further expressed as the IC₅₀ value (the concentration required to inhibit platelet aggregatory response by 50%). The values shown in the tables were calculated by linear regression from a single experimental curve with no less than four data points, each point being the mean of the percentage inhibition at a given concentration obtained from three independent experiments.

3.3. LDH Assay

3.3.1. Preparation of H9c2 Cells

H9c2 cardio myoblast cells were grown in DMEM supplemented with 10% FBS, 100 U/mL penicillin-streptomycin. Cells were cultured at 37 °C with 5% CO₂. The cells were subcultured when they reached 70–80% confluence [28]. Then the cells were seeded at 1 × 10⁴ cells per well in 96-well plate and incubated overnight. Then the cells were exposed to ginkgolide-1,2,3-triazole derivatives (1 µM and 10 µM).

3.3.2. Preparation of Washed Platelets

Rat blood was collected in 3.8% sodium citrate vacuum anticoagulant tubes and centrifuged at 100× *g* for 15 min to obtain platelet-rich plasma (PRP). The PRP was centrifuged at 1000× *g* for 10 min at 37 °C. Then the platelet pellets were suspended in Tyrode's solution (pH 7.4). The washed platelets were adjusted to 3.6 × 10⁸ platelets/mL. Washed platelets (3.6 × 10⁸ cells/mL) were pre-incubated with ginkgolide-1,2,3-triazole derivatives (1 µM and 10 µM) or 0.1% DMSO for 20 min at 37 °C, then centrifuged at 1700× *g*, 10 min and the supernatant collected [29].

3.3.3. Measurement of Lactate Dehydrogenase (LDH)

The assays to measure of LDH release were conducted in 96-well plates according to the manufacturer's protocol. The LDH levels were measured at 490 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Cell cytotoxicity was also detected by the LDH activity assay kit. Cells incubated with 0.1% dimethyl sulfoxide (DMSO) served as the control group [28,29].

4. Conclusions

In summary, a series of ginkgolide-1,2,3-triazole conjugates were synthesized through a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction of the corresponding 10-O-propargylated ginkgolides with benzyl, phenyl and heterocyclic azides. Five of them (compounds **5a**, **5p**, **5ff**, **5gg** and **5'a**) displayed promising antiplatelet aggregation activities with IC₅₀ values ranging from 5–21 nM. Compounds **5ff** and **5gg**, having a benzyl group attached at the triazole nucleus were the best among the series of compounds. The most active compounds may be regarded as safe towards normal cells and platelets at therapeutic concentrations.

Author Contributions: Conceptualization, Q.-W.Z.; Methodology, J.C., L.H. and G.C.; Investigation, J.C., L.H. and W.S.; Writing-Review & Editing, J.C. and Q.-W.Z.; Project Administration, Q.-W.Z. and X.Z.; Funding Acquisition, Q.-W.Z.

Funding: This research was funded by Macao Science and Technology Development [FDCT/113/2013/A3] and Research Committee of the University of Macau (MYRG2016-00046-ICMS-QRCM).

Acknowledgments: We gratefully acknowledge the academic and technical assistance from Yu Chang.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Maruyama, M.; Terahara, A.; Itagaki, Y.; Nakanishi, K. The ginkgolides. I. Isolation and characterization of the various groups. *Tetrahedron Lett.* **1967**, *8*, 299–302. [[CrossRef](#)]
2. Nakanishi, K.O.J.I. The ginkgolides. *Pure Appl. Chem.* **1967**, *14*, 89–114. [[CrossRef](#)] [[PubMed](#)]
3. Koch, E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: Considerations on possible bleeding complications after oral intake of *Ginkgo biloba* extracts. *Phytomedicine* **2005**, *12*, 10–16. [[CrossRef](#)] [[PubMed](#)]
4. Li, C.L.; Wong, Y.Y. The bioavailability of ginkgolides in *Ginkgo biloba* extracts. *Planta Med.* **1997**, *63*, 563–565. [[CrossRef](#)] [[PubMed](#)]
5. Zhang, X.; Li, Y.; Zhang, L.; Qin, M. A new ginkgolide from *Ginkgo biloba*. *J. China Pharm. Univ.* **2009**, *40*, 306–309.
6. Liao, H.J.; Zheng, Y.F.; Li, H.Y.; Peng, G.P. Two new ginkgolides from the leaves of *Ginkgo biloba*. *Planta Med.* **2011**, *77*, 1818–1821. [[CrossRef](#)] [[PubMed](#)]
7. Drago, F.; Floriddia, M.L.; Cro, M.; Giuffrida, S. Pharmacokinetics and bioavailability of a *Ginkgo biloba* extract. *J. Ocul. Pharmacol. Ther.* **2002**, *18*, 197–202. [[CrossRef](#)] [[PubMed](#)]
8. Marcheselli, V.L.; Rossowska, M.J.; Domingo, M.T.; Braquet, P.; Bazan, N.G. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. *J. Biol. Chem.* **1990**, *265*, 9140–9145.
9. Ishii, S.; Shimizu, T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. *Prog. Lipid Res.* **2000**, *39*, 41–82. [[CrossRef](#)]
10. Braquet, P.; Spinnewyn, B.; Braquet, M. BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from *Ginkgo biloba* L. *Blood Vessel* **1985**, *16*, 558–572. [[CrossRef](#)]
11. Braquet, P.; Drieu, K.; Etienne, A. Le Ginkgolide B (BN 52021): Un puissant inhibiteur du PAF-acether isolé du *Ginkgo biloba* L. *Actual. Chim. Ther.* **1986**, *13*, 237–254.
12. Nakanishi, K.; Habaguchi, K.; Nakadaira, Y.; Woods, M.C.; Maruyama, M.; Major, R.T.; Bähr, W. Structure of bilobalide, a rare tert-butyl containing sesquiterpenoid related to the C20-ginkgolides. *J. Am. Chem. Soc.* **1971**, *93*, 3544–3546. [[CrossRef](#)]

13. Yu, P.; Liang, J.Y. A new sesquiterpene trilactone from the roots of *Ginkgo biloba*. *Chin. Chem. Lett.* **2009**, *20*, 1224–1226. [[CrossRef](#)]
14. McKenna, D.J.; Jones, K.; Hughes, K. Efficacy, safety, and use of *Ginkgo biloba* in clinical and preclinical applications. *Altern. Ther. Health Med.* **2001**, *7*, 70–86.
15. Villhauer, E.B.; Anderson, R.C. Synthesis of the CDE ring system of the ginkgolides. *J. Org. Chem.* **1987**, *52*, 1186–1189. [[CrossRef](#)]
16. Vogensen, S.B.; Strømgaard, K.; Shindou, H.; Jaracz, S.; Suehiro, M.; Ishii, S.; Nakanishi, K. Preparation of 7-substituted ginkgolide derivatives: Potent platelet activating factor (PAF) receptor antagonists. *J. Med. Chem.* **2003**, *46*, 601–608. [[CrossRef](#)]
17. Hu, L.; Chen, Z.; Xie, Y.; Jiang, Y.; Zhen, H. Alkyl and alkoxy carbonyl derivatives of ginkgolide B: Synthesis and biological evaluation of PAF inhibitory activity. *Bioorgan. Med. Chem.* **2000**, *8*, 1505–1521. [[CrossRef](#)]
18. Park, H.K.; Lee, S.K.; Park, P.U.; Kwan, W.J. Ginkgolide Derivatives and a Process for Preparing Them. U.S. Patent Application No. 5,466,829, 14 November 1995.
19. Vatmurge, N.S.; Hazra, B.G.; Pore, V.S.; Shirazi, F.; Chavan, P.S.; Deshpande, M.V. Synthesis and antimicrobial activity of beta-lactam-bile acid conjugates linked via triazole. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2043–2047. [[CrossRef](#)] [[PubMed](#)]
20. Agalave, S.G.; Maujan, S.R.; Pore, V.S. Click chemistry: 1,2,3-triazoles as pharmacophores. *Chem. Asian J.* **2011**, *6*, 2696–2718. [[CrossRef](#)]
21. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. *Angew. Chem. Int. Ed. Engl.* **2002**, *41*, 2596–2599. [[CrossRef](#)]
22. Xu, S.; Zhuang, X.; Pan, X.; Zhang, Z.; Duan, L.; Liu, Y.; Ding, K. 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor α . *J. Med. Chem.* **2013**, *56*, 4631–4640. [[CrossRef](#)] [[PubMed](#)]
23. Yang, H.; Li, Y.; Jiang, M.; Wang, J.; Fu, H. General copper-catalyzed transformations of functional groups from arylboronic acids in water. *Chem. Eur. J.* **2011**, *17*, 5652–5660. [[CrossRef](#)] [[PubMed](#)]
24. Yuhong, J.; Dalip, K.; Rajender, S.V. Revisiting nucleophilic substitution reactions: Microwave-assisted synthesis of azides, thiocyanates, and sulfones in an aqueous medium. *J. Org. Chem.* **2006**, *71*, 6697–6700.
25. Diaz, L.; Bujons, J.; Casas, J.; Llebaria, A.; Delgado, A. Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease. *J. Med. Chem.* **2010**, *53*, 5248–5255. [[CrossRef](#)] [[PubMed](#)]
26. Born, G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature* **1962**, *194*, 927–929. [[CrossRef](#)] [[PubMed](#)]
27. Jun, T.; Ke-yan, F. Experimental and clinical studies on inhibitory effect of *Ganoderma lucidum* on platelet aggregation. *J. Tongji Med. Univ.* **1990**, *10*, 240–243. [[CrossRef](#)]
28. Zhang, Y.; Deng, H.; Zhou, H.; Lu, Y.; Shan, L.; Lee, S.M.; Cui, G. A novel agent attenuates cardiotoxicity and improves antitumor activity of doxorubicin in breast cancer cells. *J. Cell. Biochem.* **2019**, *120*, 5913–5922. [[CrossRef](#)]
29. Zou, J.; Chen, Y.; Hoi, M.P.M.; Li, J.; Wang, T.; Zhang, Y.; Feng, Y.; Gao, J.; Lee, S.M.Y.; Cui, G. Discovery of a novel ERp57 inhibitor as antiplatelet agent from danshen (*Salvia miltiorrhiza*). *Evid. Based Complement. Altern. Med.* **2018**, *2018*, 9387568. [[CrossRef](#)]

Sample Availability: Samples of the compounds **5a–5gg**, **5'a–5'gg**, **5''a–5''gg** are available from the authors.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).